Literature DB >> 6408155

Nomifensine decreases the thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in normal subjects.

M Giusti, G Mazzocchi, D Mignone, W Tarditi, G Giordano.   

Abstract

The Thyroid-stimulating-hormone (TSH) secretion has been studied in 12 normal euthyroid subjects (4 males, 8 females) after nomifensine (NOM) administration (200 mg po). NOM is a drug which activates dopaminergic neurotransmission at the Central Nervous System level. Blood samples were drawn every h for 4 h after NOM or placebo, respectively. At the 4th hour thyrotropin-releasing-hormone (TRH) was administered in bolus (200 micrograms iv), in both studies, and additional samples were collected for 90 min. The results show a moderate suppression (NS) of TSH and a clear-cut reduction in the secretory response to TRH after NOM administration (secretory area: TRH after placebo 723 +/- 132, TRH after NOM 400 +/- 83; p less than 0.01). The data appear to confirm that dopaminergic neurotransmission exerts an inhibitory role upon TSH secretion. The mechanism by which NOM induced dopaminergic activation leads to the suppression of TSH release after TRH has not yet been elucidated. An interference in TSH storage and/or in the post receptor mechanisms involved in TRH action might be hypothesized.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408155     DOI: 10.1007/BF03350584

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Human prolactin and growth hormone release during surgery and other conditions of stress.

Authors:  G L Noel; H K Suh; J G Stone; A G Frantz
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

2.  A new pharmacological approach to the diagnosis of hyperprolactinaemic states: the nomifensine test.

Authors:  A R Genazzani; F Camanni; F Massara; E Picciolini; D Cocchi; L Belforte; E E Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1980-02

3.  Interrelationships in the regulation of TSH and prolactin secretion in man: effects of L-dopa, TRH and thyroid hormone in various combinations.

Authors:  S Refetoff; V S Fang; B Rapoport; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

4.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.

Authors:  P Hunt; M Kannengiesser; J Raynaud
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

5.  Effect of bromoergocriptine on TRH-induced growth hormone and prolactin release in acromegalic patients.

Authors:  M Ishibashi; T Yamaji; K Kosaka
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

6.  Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.

Authors:  J M Rabey; Y Vardi; R Ravid; D Ayalon
Journal:  Horm Res       Date:  1981

7.  Evidence for dopaminergic control of thyrotrophin secretion in man.

Authors:  M F Scanlon; D R Weightman; B Mora; M Heath; D J Shale; M H Snow; R Hall
Journal:  Lancet       Date:  1977-08-27       Impact factor: 79.321

8.  Increased thyrotrophin secretion induced by sulpiride in man.

Authors:  F Massara; F Camanni; L Belforte; V Vergano; G M Molinatti
Journal:  Clin Endocrinol (Oxf)       Date:  1978-11       Impact factor: 3.478

9.  Nomifensine: diagnostic test in hyperprolactinemic states.

Authors:  E E Müller; A R Genazzani; S Murru
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

10.  Inhibition of prolactin secretion by nomifensine in man.

Authors:  A Masala; S Alagna; L Devilla; G Delitala; P P Rovasio
Journal:  Clin Endocrinol (Oxf)       Date:  1980-03       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.